All stock lists
Addus HomeCare Corp (NASDAQ:ADUS)
US · Delayed Price · Currency is USD
Healthcare · Medical - Care Facilities
126.29+3.87 (+3.16%)
Market cap
$2.35B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 28, 2009
Website
Insider Score
––Not scored
ADUS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ADUS analyst forecast
ADUS analyst consensus
Hold5 ratings
Buy 3 Hold 1 Sell 1
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ADUS 12-month price target
$142.50+12.8% upsideaverage of 2 firms
$148.00High
$137.00Low
ADUS ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ADUS
- Stephens & Co.64%success rate · +9.7% avg return · 14 calls
- TD Cowen60%success rate · -0.3% avg return · 5 calls
- RBC Capital47%success rate · +2.3% avg return · 15 calls
- Barclays0%success rate · -7.4% avg return · 3 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ADUS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | UBS | Buy | — | — | Reiterated | 2026-11-05 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-11-05 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-11-05 |
| Truist Financial | — | $148.00 | +15.7% | — | 2026-11-05 | |
| — | Barclays | Underweight | — | — | Reiterated | 2026-11-04 |
| Raymond James | — | $137.00 | +21.0% | — | 2026-09-28 | |
| — | B of A Securities | Neutral | — | — | Downgraded | 2026-09-14 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-08-05 |
| — | Barclays | Underweight | — | — | Reiterated | 2026-07-09 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-05-18 |
| — | Barclays | Underweight | — | — | Reiterated | 2026-05-15 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-05-06 |
| — | Barclays | Underweight | — | — | Reiterated | 2026-03-25 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2026-02-25 |
| — | Barclays | Underweight | — | — | Reiterated | 2026-02-24 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-07 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-11-05 |
| — | Barclays | Underweight | — | — | Reiterated | 2025-11-04 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2025-09-03 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-22 |
| — | Barclays | Underweight | — | — | Reiterated | 2025-08-19 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-08-06 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-07-31 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-07-16 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-06-20 |
| — | Macquarie | Outperform | — | — | Reiterated | 2025-06-10 |
| — | Macquarie | Outperform | — | — | Reiterated | 2025-05-08 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-04-22 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-04-10 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2025-03-12 |
| — | Macquarie | Outperform | — | — | Reiterated | 2025-02-27 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2025-02-26 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-01-24 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-11-14 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2024-11-06 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-11-06 |
| — | Macquarie | Outperform | — | — | Reiterated | 2024-11-04 |
| — | Macquarie | Outperform | — | — | Reiterated | 2024-10-11 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-09-23 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-09-03 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-08-08 |
| — | TD Cowen | Buy | — | — | Reiterated | 2024-08-08 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2024-08-07 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-08-07 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2024-08-06 |
| — | TD Cowen | Buy | — | — | Reiterated | 2024-06-18 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-06-07 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2024-05-31 |
| — | TD Cowen | Buy | — | — | Reiterated | 2024-05-09 |
| — | B of A Securities | Buy | — | — | Reiterated | 2024-05-07 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2024-05-07 |
| — | Barclays | Underweight | — | — | Downgraded | 2024-04-23 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-03-26 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-02-29 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-01-17 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2023-11-01 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2023-11-01 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-08-02 |
| — | Raymond James | Outperform | — | — | Reiterated | 2023-08-02 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2023-08-02 |
ADUS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-23 | 1.71 | 1.77 | $372.9M | $372.1M |
| 2026-05-04 | 1.52 | 1.62 | $366.4M | $363.5M |
| 2026-08-03 | 1.70 | 1.73 | $376.2M | $377.4M |
| 2026-11-03 | 1.79 | 1.83 | $388.7M | $387.7M |
| 2027-02-22Upcoming | 1.90 | — | $394.7M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.